Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Unknown 2Withdrawn 1Recruiting 1Not yet recruiting 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Stomach Neoplasms 1MCRC 1Lymphopenia 1Hematologic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 115Carboplatin 103Pemetrexed 90Cisplatin 58Paclitaxel 47osimertinib 41Drug Therapy 40Nivolumab 39Docetaxel 35Specimen Handling 33Magnetic Resonance Spectroscopy 28Bevacizumab 26durvalumab 23Gemcitabine 22cemiplimab 21Radiotherapy 20130-nm albumin-bound paclitaxel 20Radiosurgery 19tislelizumab 18atezolizumab 17aflutinib 15Cetuximab 15Immunotherapy 14Immune Checkpoint Inhibitors 14Platinum Compounds 13Ipilimumab 13Biopsy 12Standard of Care 11Surgical Procedures, Operative 10Injections 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Non-Small-Cell Lung × Thymalfasin × Clear all
NCT06598839 2024-09-19

Immuno-effect of Tα1 for Stage I NSCLC

Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Phase NA Recruiting
40 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡